Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Recurrent Mantle Cell Lymphoma Clinical Trial

Official title:

Phase 1/2 Study to Evaluate the Safety, Feasibility, and Efficacy of FP-1201 (Intravenous Interferon-Beta-1a) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05936229
• Other study ID #: RG1123521
• Secondary ID: NCI-2023-0488820
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: April 1, 2025
• Est. completion date: October 30, 2027

Study information

• Verified date: May 2024
• Source: Fred Hutchinson Cancer Center
• Contact: Fred Hutch Immunotherapy Intake
• Phone: 206-606-4668
• Email: immunotherapy[@]fredhutch.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I/II trial tests the safety and how well intravenous interferon-beta-1a (FP-1201) works in preventing toxicities after CD19-directed chimeric antigen receptor (CAR) T-cell therapy in patients with B-cell cancers that has come back after a period of improvement (recurrent) or that has not responded to previous treatment (refractory). Interferon beta-1a is in a class of medications called immunomodulators. It works by protecting the lining of blood vessels, and preventing brain inflammation. Giving FP-1201 may prevent cytokine release syndrome (CRS) and immune effector cell associated-neurotoxicity syndrome (ICANS) toxicities in patients receiving CD19 CAR T-cell therapy with recurrent or refractory B-cell malignancies.

Description:

OUTLINE: This is a dose-escalation study of FP-1201.

Patients undergo leukapheresis prior to treatment and receive FP-1201 intravenously (IV) for 3 days every 24 hours from day -3 through day -1 or for 5 days every 24 hours from day -5 through day -1 or on day -5, day -3, and day -1. Patients may receive lymphodepletion chemotherapy with either cyclophosphamide IV and fludarabine IV on days -5, -4, -3 followed by axi-cel IV or brexu-cel IV on day 0 or fludarabine IV over 30 minutes on days -4, -3, and -2 and cyclophosphamide IV over 60 minutes on day -2 followed by brexu-cel IV on day 0. Patients undergo x-ray imaging and echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening. Patients also undergo computed tomography (CT) or positron emission tomography (PET)/CT as well as lumbar puncture (LP) for cerebral spinal fluid (CSF) collection and/or bone marrow aspiration and biopsy as clinically indicated during screening and follow-up. Patients undergo blood sample collection on study and during follow-up as well as a tissue biopsy during screening and follow-up.

After completion of study treatment, patients are followed up to 28 days and 90 days, then long-term for up to 15 years.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 24
• Est. completion date: October 30, 2027
• Est. primary completion date: October 30, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants must be 18 years of age or older

• Karnofsky performance status of >= 60%

• Participants eligible for treatment with axi-cel or brexu-cel

• Negative serum pregnancy test within 2 weeks of enrollment for women of childbearing potential, defined as those who have not been surgically sterilized or who have not been free of menses for at least 1 year

• Fertile male and female participants must be willing to use an effective contraceptive method before, during, and for at least 4 months after the last dose of FP-1201

• Ability to understand and provide informed consent

Exclusion Criteria:

• Known hypersensitivity to natural or recombinant interferon beta, albumin or any other component of the formulation

• Estimated creatinine clearance (Cockcroft and Gault) =< 60 mL/min

• Significant proteinuria defined as 2+ or 3+ proteinuria or urinary protein >= 1g/24h

• Severe hepatic dysfunction defined as group C of the National Cancer Institute Organ Dysfunction Working Group hepatic impairment criteria (total bilirubin > 3x upper limit of normal [ULN] with any aspartate aminotransferase [AST] or alanine transaminase [AL]T value), or AST or ALT > 3x ULN, unless due to malignancy or Gilbert's syndrome in the opinion of the principal investigator (PI) or designee

• Participants with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing, as clinically indicated. Those with an forced expiratory volume in the first second (FEV1) of < 50 % of predicted or diffusing capacity of the lungs for carbon monoxide (DLCO) (corrected) < 40% will be excluded

• Significant cardiovascular abnormalities as defined by any one of the following:

• New York Heart Association (NYHA) class III or IV congestive heart failure, clinically significant hypotension

• Uncontrolled symptomatic coronary artery disease, or a documented ejection fraction of < 35%

• Uncontrolled serious and active infection

• Corticosteroid use (> 20mg/day of prednisone, or equivalent) within 7 days prior to first FP-1201 administration

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Lymphoid
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Mantle-Cell
• Lymphoma, Non-Hodgkin
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Recurrence
• Recurrent B Acute Lymphoblastic Leukemia
• Recurrent B-Cell Non-Hodgkin Lymphoma
• Recurrent Mantle Cell Lymphoma
• Refractory B Acute Lymphoblastic Leukemia
• Refractory B-Cell Non-Hodgkin Lymphoma
• Refractory Mantle Cell Lymphoma

Intervention

Biological:
• Interferon Beta-1A
Given IV

Procedure:
• X-Ray Imaging
Undergo x-ray
• Echocardiography
Undergo ECHO
• Multigated Acquisition Scan
Undergo MUGA
• Computed Tomography
Undergo CT
• Positron Emission Tomography
Undergo PET/CT
• Lumbar Puncture
Undergo LP
• Bone Marrow Aspiration
Undergo bone marrow aspiration
• Bone Marrow Biopsy
Undergo bone marrow biopsy
• Biospecimen Collection
Undergo blood and CSF sample collection
• Biopsy
Undergo tissue biopsy

Locations

Country	Name	City	State
United States	Fred Hutch/University of Washington Cancer Consortium	Seattle	Washington

Sponsors (2)

Lead Sponsor	Collaborator
Fred Hutchinson Cancer Center	Faron Pharmaceuticals Ltd

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose-limiting toxicity (DLT) rates	Will be summarized in the DLT evaluable population. Final DLT rates at each dose level will be estimated by isotonic regression by applying the pooled adjacent violators algorithm. The target toxicity rate is 30%.	Within 14 days after the last administration of interferon-beta-1a (FP-1201)
Primary	Incidence of adverse events (AEs)	Type, frequency, and severity of AEs according to the National Cancer Institutes Common Terminology Criteria for Adverse Events version 5.0.	From the first dose of FP-1201 through day 28 after chimeric antigen receptor (CAR) T-cell infusion
Secondary	Cytokine release syndrome (CRS) rates	Will be assessed by any grade and grade >= 3 by American Society for Transplantation and Cellular Therapy (ASTCT) criteria and will be summarized along the two-sided 95% Clopper-Pearson confidence interval (CI) based on the CRS and ICANS analysis set.	From the time of CAR T-cell infusion through day 28 after CAR T-cell infusion or until resolution, whichever happens last
Secondary	Immune effector cell associated-neurotoxicity syndrome (ICANS) rates	Will be assessed by any grade and grade >= 3 by ASTCT criteria and will be summarized along the two-sided 95% Clopper-Pearson CI based on the CRS and ICANS analysis set.	From the time of CAR T-cell infusion through day 28 after CAR T-cell infusion or until resolution, whichever happens last
Secondary	Cumulative corticosteroids dose	Will be summarized using descriptive statistics (median, quantiles) based on the CRS and ICANS analysis set.	Within 28 days after CAR T-cell infusion
Secondary	Overall response rate	Will be assessed by the Lugano criteria for B-non-Hodgkin lymphoma (NHL) participants and National Comprehensive Cancer Network (NCCN) criteria for B- acute lymphoblastic leukemia (ALL) participants Will be summarized along with the two-sided Clopper-Pearson CI based on the anti-tumor response evaluable analysis set.	28 days after CAR T-cell infusion
Secondary	Complete response rate	Will be assessed by the Lugano criteria for B-NHL participants and NCCN criteria for B-ALL participants Will be summarized along with the two-sided Clopper-Pearson CI based on the anti-tumor response evaluable analysis set.	28 days after CAR T-cell infusion